Quotient Sciences has extended a commercial partnership with Ipsen to produce Sohonos (palovarotene) for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.[1][2] The partnership will ensure a continuous commercial supply of this highly potent drug, which requires special handling to protect the facility and workers.[1][2] Sohonos was approved by the FDA in 2023 as a retinoid to reduce the volume of newly formed heterotopic ossification in adults and children aged 8 years in girls and 10 years in boys with FOP.[1][2][3] Ipsen invested in new equipment at the Quotient Sciences plant in Boothwyn, Pennsylvania, including a pneumatic closed transfer system for safe material transfer and flexible isolation dispensing equipment to increase operator safety.[1][2] These improvements eliminate special purification and support the handling of more highly potent compounds.[1][2] Quotient Sciences provides a world-class facility, experienced team, reliable supply and global distribution.[1][2] The partnership emphasizes support for niche, low-volume products that are often overlooked by larger CDMOs.[1][2]